🔎 Trials Near Me

Home › Psoriatic Arthritis › NCT07486960

Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)

RecruitingPhase 2

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Psoriatic Arthritis.

Who can join

Ages 18 to 80 · All sexes

Full eligibility criteria
Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* Has a clinical diagnosis of PsA and fulfillment of the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria at Screening, with symptom onset ≥6 months before Screening.
* Has a diagnosis of active plaque psoriasis or documented history of plaque psoriasis.
* Has history of biologic disease-modifying antirheumatic drug (bDMARD)-naïve or bDMARD-inadequate response/intolerant.

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

* Has any arthritis with onset before age 17 years or current diagnosis of inflammatory joint disease other than PsA (such as, but not limited to, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, myositis, etc), or any other conditions that may, in the judgment of the investigator, interfere with the assessment of PsA.
* Has a skin condition diagnosis, other than psoriasis that may, in the judgment of the investigator, interfere with the assessment of psoriasis.
* Has a history of cancer (except fully treated nonmelanoma skin cancers or cervical carcinoma in situ after complete surgical removal) and is disease free for \<5 years before Randomization.
* Has any active infection.
* Has known allergies, hypersensitivity, or intolerance to tulisokibart of its excipients.

About the study

Researchers are looking for new ways to treat Psoriatic Arthritis (PsA). This study will help find out if a study medicine called tulisokibart (MK-7240) can treat symptoms of active PsA. This study assesses the efficacy, safety, and tolerability of tulisokibart in adult participants with active PsA.

In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen PsA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.

What is being tested

Sponsor: Merck Sharp & Dohme LLC · Participants: 140 · Started: Apr 20, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07486960

Locations in the U.S.

ArizonaArizona Arthritis & Rheumatology Associates, P.C. ( Site 5117), Sun City
Arizona Arthritis & Rheumatology Associates, P.C. - Tucson ( Site 5120), Tucson
CaliforniaMedvin Clinical Research - Riverside ( Site 5115), Riverside
Cohen Medical Centers ( Site 5111), Thousand Oaks
Medvin Clinical Research - Tujunga ( Site 5113), Tujunga
FloridaArthritis and Rheumatic Disease Specialties ( Site 5105), Aventura
International Center for Research ( Site 5124), Tampa
IdahoSt. Luke's Clinic - Rheumatology - Boise ( Site 5109), Boise
MarylandJohns Hopkins Bayview Medical Center - Johns Hopkins Asthma & Allergy Center ( Site 5132), Baltimore
Arthritis and Rheumatism Associates - Rockville ( Site 5127), Rockville
MissouriKansas City Physician Partners ( Site 5119), Kansas City
NebraskaPhysician Research Collaboration, LLC ( Site 5102), Lincoln
New YorkJoseph S. and Diane H. Steinberg Ambulatory Care Center ( Site 5106), Brooklyn
North CarolinaJoint and Muscle Research Institute ( Site 5108), Charlotte
PennsylvaniaAltoona Center for Clinical Research ( Site 5110), Duncansville
Hospital of the University of Pennsylvania ( Site 5134), Philadelphia
South CarolinaArticularis Healthcare Group dba: Low Country Rheumatology ( Site 5128), Summerville
TexasGreater Houston Rheumatology ( Site 5103), Houston

Conditions

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.